Indeed, studies have demonstrated significantly elevated TSPO levels in MS patients compared to healthy controls, underscoring the utility of TSPO PET as a biomarker of disease activity and a potential endpoint for therapeutic trials 136. This evidence concerns the gene TSPO and myeloid sarcoma.